Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

Completed · Phase 2 · Has a placebo group

Conditions studied: Alcoholism, Alcohol Abuse

In brief

This study is being done to determine if citalopram is safe and effective in the treatment of alcohol dependence. A second purpose is to evaluate whether alcohol dependent individuals who differ in a specific genetic marker respond differently to citalopram. Citalopram is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of depression. It belongs to a category of medications called selective serotonin re-uptake inhibitors or SSRIs. The U.S. FDA has not approved citalopram for the treatment of alcohol dependence. Therefore, it is being used "off-label" in this study.

Key facts

Study ID

NCT00249405

Run by

University of Cincinnati

People needed

200

Starts

2005-02-01

Expected to finish

2010-10-01

Last updated by the study team

2010-11-03

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients with a diagnosis of DSM-IV alcohol dependence
• Not morbidly obese or underweight
• Express desire to quit or cut down on drinking for duration of trial

You may not qualify if…

• Clinically significant laboratory evidence of diseases
• Have active psychological disorders other than alcoholism

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.